Endometriosis - Pipeline Review, H2 2016

Endometriosis - Pipeline Review, H2 2016

  • Products Id :- GMDHC8457IDB
  • |
  • Pages: 132
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Endometriosis - Pipeline Review, H2 2016


Global Markets Direct's, 'Endometriosis - Pipeline Review, H2 2016', provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Endometriosis

- The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects

- The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Endometriosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Endometriosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Endometriosis Overview 11

Therapeutics Development 12

Pipeline Products for Endometriosis - Overview 12

Pipeline Products for Endometriosis - Comparative Analysis 13

Endometriosis - Therapeutics under Development by Companies 14

Endometriosis - Therapeutics under Investigation by Universities/Institutes 16

Endometriosis - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Endometriosis - Products under Development by Companies 21

Endometriosis - Products under Investigation by Universities/Institutes 24

Endometriosis - Companies Involved in Therapeutics Development 25

AbbVie Inc 25

Addex Therapeutics Ltd 26

APAvadis Biotechnologies Srl 27

Astellas Pharma Inc. 28

Bayer AG 29

Dongkook Pharmaceutical Co., Ltd. 30

ElexoPharm GmbH 31

EndoCeutics, Inc. 32

Enteris BioPharma, Inc. 33

Euroscreen S.A. 34

Evotec AG 35

Forendo Pharma Limited 36

GlaxoSmithKline Plc 37

Kissei Pharmaceutical Co., Ltd. 38

Lipicard Technologies Limited 39

Luye Pharma Group Ltd. 40

Nippon Shinyaku Co., Ltd. 41

Orphagen Pharmaceuticals, Inc. 42

Philogen S.p.A. 43

Repros Therapeutics Inc. 44

SK Chemicals Co., Ltd. 45

Takeda Pharmaceutical Company Limited 46

ValiRx Plc 47

Endometriosis - Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Combination Products 49

Assessment by Target 50

Assessment by Mechanism of Action 53

Assessment by Route of Administration 56

Assessment by Molecule Type 58

Drug Profiles 60

acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

ASP-1707 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

BAY-1128688 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

bentamapimod - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Drug to Inhibit C-Jun for Endometriosis - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Drugs for Endometriosis - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Drugs for Endometriosis and Uterine Fibroids - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

elagolix sodium - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

epelsiban besylate - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

ESN-364 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

EVE-104 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

FP-5677 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

goserelin biosimilar - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

goserelin ER - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

KLH-2109 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

leuprolide acetate - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

LT-6121 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

MIA-602 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

NS-580 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Peptides for Endometriosis and Hepatic Tumor - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

PGL-2001 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

relugolix - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

SKI-2670 - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

SR-16234 - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

telapristone acetate - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

Tetravil - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

triptorelin biosimilar - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

VAL-201 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

vilaprisan - Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

VPE-001 - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

VPEA-004 - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

Endometriosis - Dormant Projects 119

Endometriosis - Discontinued Products 121

Endometriosis - Product Development Milestones 122

Featured News & Press Releases 122

Aug 05, 2016: Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis 122

Jul 06, 2016: ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis 122

Mar 31, 2016: ValiRx is exhibiting and presenting at the prestigious AACR 123

Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis 123

Dec 21, 2015: Repros Updates Proellex Program 124

Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA 124

Feb 26, 2015: New Endometriosis Patent Grant for ValiRx 125

Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications 126

Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis 126

Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 127

Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 128

Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 128

Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 128

Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 129

Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis 129

Appendix 131

Methodology 131

Coverage 131

Secondary Research 131

Primary Research 131

Expert Panel Validation 131

Contact Us 131

Disclaimer 132

List of Figures

Number of Products under Development for Endometriosis, H2 2016 12

Number of Products under Development for Endometriosis - Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 48

Number of Products by Top 10 Targets, H2 2016 50

Number of Products by Stage and Top 10 Targets, H2 2016 50

Number of Products by Top 10 Mechanism of Actions, H2 2016 53

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 53

Number of Products by Routes of Administration, H2 2016 56

Number of Products by Stage and Routes of Administration, H2 2016 56

Number of Products by Molecule Types, H2 2016 58

Number of Products by Stage and Molecule Types, H2 2016 58

List of Tables

Number of Products under Development for Endometriosis, H2 2016 12

Number of Products under Development for Endometriosis - Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Comparative Analysis by Unknown Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Development by Companies, H2 2016 (Contd..2) 23

Products under Investigation by Universities/Institutes, H2 2016 24

Endometriosis - Pipeline by AbbVie Inc, H2 2016 25

Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2016 26

Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2016 27

Endometriosis - Pipeline by Astellas Pharma Inc., H2 2016 28

Endometriosis - Pipeline by Bayer AG, H2 2016 29

Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016 30

Endometriosis - Pipeline by ElexoPharm GmbH, H2 2016 31

Endometriosis - Pipeline by EndoCeutics, Inc., H2 2016 32

Endometriosis - Pipeline by Enteris BioPharma, Inc., H2 2016 33

Endometriosis - Pipeline by Euroscreen S.A., H2 2016 34

Endometriosis - Pipeline by Evotec AG, H2 2016 35

Endometriosis - Pipeline by Forendo Pharma Limited, H2 2016 36

Endometriosis - Pipeline by GlaxoSmithKline Plc, H2 2016 37

Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 38

Endometriosis - Pipeline by Lipicard Technologies Limited, H2 2016 39

Endometriosis - Pipeline by Luye Pharma Group Ltd., H2 2016 40

Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 41

Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 42

Endometriosis - Pipeline by Philogen S.p.A., H2 2016 43

Endometriosis - Pipeline by Repros Therapeutics Inc., H2 2016 44

Endometriosis - Pipeline by SK Chemicals Co., Ltd., H2 2016 45

Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 46

Endometriosis - Pipeline by ValiRx Plc, H2 2016 47

Assessment by Monotherapy Products, H2 2016 48

Assessment by Combination Products, H2 2016 49

Number of Products by Stage and Target, H2 2016 51

Number of Products by Stage and Mechanism of Action, H2 2016 54

Number of Products by Stage and Route of Administration, H2 2016 57

Number of Products by Stage and Molecule Type, H2 2016 59

Endometriosis - Dormant Projects, H2 2016 119

Endometriosis - Dormant Projects (Contd..1), H2 2016 120

Endometriosis - Discontinued Products, H2 2016 121

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

AbbVie Inc

Addex Therapeutics Ltd

APAvadis Biotechnologies Srl

Astellas Pharma Inc.

Bayer AG

Dongkook Pharmaceutical Co., Ltd.

ElexoPharm GmbH

EndoCeutics, Inc.

Enteris BioPharma, Inc.

Euroscreen S.A.

Evotec AG

Forendo Pharma Limited

GlaxoSmithKline Plc

Kissei Pharmaceutical Co., Ltd.

Lipicard Technologies Limited

Luye Pharma Group Ltd.

Nippon Shinyaku Co., Ltd.

Orphagen Pharmaceuticals, Inc.

Philogen S.p.A.

Repros Therapeutics Inc.

SK Chemicals Co., Ltd.

Takeda Pharmaceutical Company Limited

ValiRx Plc

Endometriosis Therapeutic Products under Development, Key Players in Endometriosis Therapeutics, Endometriosis Pipeline Overview, Endometriosis Pipeline, Endometriosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 146940
Site License
USD 4000 INR 293880
Corporate User License
USD 6000 INR 440820



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com